Criticisms of drugs in early development for the treatment of depression: what can be improved? (Q48148268)

9 February 2018

editorial

0 references

title

Criticisms of drugs in early development for the treatment of depression: what can be improved? (English)

1 reference

9 February 2018

author name string

Sheng-Min Wang

series ordinal

1

1 reference

9 February 2018

Changsu Han

series ordinal

2

1 reference

9 February 2018

Chi-Un Pae

series ordinal

3

1 reference

9 February 2018

language of work or name

English

0 references

publication date

20 December 2014

1 reference

9 February 2018

Expert Opinion on Investigational Drugs

published in

1 reference

9 February 2018

volume

24

1 reference

9 February 2018

issue

4

1 reference

9 February 2018

page(s)

445-453

1 reference

9 February 2018

Current investigational drugs for major depression

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.985784

Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.985784

21 January 2018

The Serotonin Syndrome

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.985784

Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.985784

Pharmacokinetic evaluation of vortioxetine for the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.985784

Vilazodone in the treatment of major depressive disorder: efficacy across symptoms and severity of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.985784

A review of current evidence for vilazodone in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.985784

Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.985784

A randomized trial on the acute and steady-state effects of a new antidepressant, vortioxetine (Lu AA21004), on actual driving and cognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.985784

A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.985784

A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.985784

Vortioxetine for the treatment of major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.985784

A proposal for an updated neuropsychopharmacological nomenclature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.985784

A randomized, double-blind study comparing LY2216684 and placebo in the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.985784

A study of the effects of LY2216684, a selective norepinephrine reuptake inhibitor, in the treatment of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.985784

A double-blind, placebo-controlled study of edivoxetine as an adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.985784

Triple Reuptake Inhibitors: A Premise and Promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.985784

Triple reuptake inhibitors: a patent review (2006 - 2012).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.985784

Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.985784

An open pilot study of the combination of escitalopram and bupropion-SR for outpatients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.985784

Does dual antidepressant therapy as initial treatment hasten and increase remission from depression?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.985784

A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.985784

Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.985784

The combination of duloxetine and bupropion for treatment-resistant major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.985784

Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.985784

Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.985784

Triple reuptake inhibitors: the next generation of antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.985784

The well of novel antidepressants: running dry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.985784

An analysis of adaptive design variations on the sequential parallel comparison design for clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.985784

Is there a placebo problem in antidepressant trials?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.985784

Innovations in clinical research design and conduct in psychiatry: shifting to pragmatic approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.985784

Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.985784

Efficacy of antidepressants: a re-analysis and re-interpretation of the Kirsch data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.985784

No role for initial severity on the efficacy of antidepressants: results of a multi-meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.985784

New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates--Nrf2 activators and GSK-3 inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.985784

Oxidative/nitrosative stress and antidepressants: targets for novel antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.985784

NMDA antagonists under investigation for the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.985784

Antidepressant effects of ketamine in depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.985784

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.985784

Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.985784

A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.985784

Scopolamine and depression: a role for muscarinic antagonism?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.985784

Acute stress increases depolarization-evoked glutamate release in the rat prefrontal/frontal cortex: the dampening action of antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.985784

Glucocorticoid prevents brain-derived neurotrophic factor-mediated maturation of synaptic function in developing hippocampal neurons through reduction in the activity of mitogen-activated protein kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.985784

Ketamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.985784

Oral scopolamine augmentation for major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.985784

Scopolamine as an antidepressant: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.985784

A review of current evidence for acetyl-l-carnitine in the treatment of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.985784

Neurobiological advances identify novel antidepressant targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.985784

Role of immunological factors in the pathophysiology and diagnosis of bipolar disorder: comparison with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.985784

Pharmacological blockade of 5-HT7 receptors as a putative fast acting antidepressant strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.985784

5-HT7, neurogenesis and antidepressants: a promising therapeutic axis for treating depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.985784

Monoamine neurocircuitry in depression and strategies for new treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.985784

Neurotransmitter targeting in the treatment of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.985784

Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.985784

The role of extended-release quetiapine fumarate monotherapy in the treatment of patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.985784

Stress, depression, and neuroplasticity: a convergence of mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.985784

miR-1202 is a primate-specific and brain-enriched microRNA involved in major depression and antidepressant treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.985784

10.1517/13543784.2014.985784

21 January 2018

Identifiers

DOI

1 reference

9 February 2018

PubMed ID

25529224

1 reference

9 February 2018